Wells Fargo & Company Forecasts Strong Price Appreciation for Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics (NASDAQ:BCAX) had its target price raised by analysts at Wells Fargo & Company from $11.00 to $16.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential downside of 21.95% from the company’s previous close.

A number of other research analysts have also issued reports on the stock. Bank of America began coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective for the company. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, Citigroup initiated coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Stock Up 3.1%

Shares of BCAX stock opened at $20.50 on Tuesday. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $21.05. The stock’s fifty day simple moving average is $17.28 and its 200 day simple moving average is $16.69. The firm has a market capitalization of $1.34 billion, a P/E ratio of -8.10 and a beta of -1.24.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.04. As a group, equities research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider David Raben sold 16,300 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider directly owned 55,286 shares in the company, valued at $1,023,896.72. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Ryan Cohlhepp sold 17,392 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $18.16, for a total transaction of $315,838.72. Following the sale, the chief operating officer directly owned 205,141 shares of the company’s stock, valued at $3,725,360.56. This represents a 7.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 137,969 shares of company stock valued at $2,586,198 in the last ninety days. Insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth $45,000. Legal & General Group Plc lifted its holdings in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares during the period. Larson Financial Group LLC boosted its position in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the last quarter.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.